Buy Omeprazole-Teva enteric capsules

Omeprazole-Teva enteric capsules

31016USD

Description

Features

Reviews ¹

Instructions for Omeprazole-Teva enteric capsules

English Product Name
Omeprazole-Teva

Release Form
caps. enteric soluble 20 mg: 14, 28 or 30 pcs.

Description Omeprazole

Intestinal soluble white opaque solid gelatin capsules, No. 2; black ink is applied on the lid "O", on the case - "20"; capsule contents - micropellets from white to white with a yellowish or pinkish shade of color.

1 caps.
omeprazole 20.00 mg
Auxiliary substances: granulated sugar [sucrose, starch paste] - 86.98 mg, sodium carboxymethyl starch type A - 5.10 mg, sodium lauryl sulfate - 6.07 mg, povidone K30 - 9.66 mg, sodium phosphate dodecahydrate - 0.67 mg, sodium hydroxide - 0.14 mg, hypromellose - 14.42 mg, methacrylic acid and ethyl acrylate copolymer [1:1] - 42.5 3 mg, triethyl citrate 6.17 mg, titanium dioxide (E171) 3.31 mg, talc 0.19 mg.

The composition of the lid of the gelatin capsule: titanium dioxide (E171) - 0.48-0.504 mg, water - 3.48-3.654 mg, gelatin - 20.04-23.912 mg.
The body composition of the gelatin capsule: titanium dioxide (E171) - 0.732-0.78 mg, water - 5.481-5.655 mg, gelatin - 31.563-35.868 mg.
The composition of black ink: shellac - 24-27%, ethanol* - 23-26%, isopropanol* - 1-3%, propylene glycol - 3-7%, butanol* - 1-3%, ammonia aqueous - 1-2%, potassium hydroxide - 0.05-0.1%, water - 15-18%, iron oxide black dye (E172) - 24-28%.

* Ethanol, isopropanol, butanol evaporate completely during capsule and capsule inscription

ATX codes
A02BC01 Omeprazole

Clinical and pharmacological groups / Group affiliation
An H<SUP>+</SUP>-K<SUP>+</SUP>-ATP-ase inhibitor. Antiulcer drug

Active ingredient
omeprazole

Pharmacotherapeutic group Omeprazole

Gastric gland secretion reducing agent - proton pump inhibitor

Effect pharmacological

A drug that slows down the base enzyme in the stomach cells and thus blocks hydrochloric acid production. This results in less acid production, regardless of stimulation. Reducing acidity may reduce esophageal irritation in patients with reflux esophagitis.

In addition, the drug has a deadly effect on the bacterium Helicobacter pylori. The use of the drug in combination with antibiotics helps to quickly cope with the symptoms of the disease, improve the condition of the mucosa and reduce the likelihood of bleeding from the gastrointestinal tract.

Testimony Omeprazole

Gastric and duodenal mucosal disease of increasing severity (including helicobacter pylori-associated disease), reflux esophagitis, zollinger-ellison syndrome, nsaids-induced gastric and duodenal erosion.

Method of use, period and dosage Omeprazole

Individual approach. Oral dosing is 20 to 40 mg once.
Daily dose is 20-80 mg; frequency of use is 1-2 times a day. Duration of treatment is 2-8 weeks.